Acumen Pharmaceuticals, Inc.

ABOS

Healthcare|Biotechnology|US

$0.22

+0.01 (+4.54%)

DCF Value

$0.38

Tangible Book / Share

$0.48

Cash / Share

$1.09

Next Earnings Report

Mar 25, 2027

EPS est. -$0.37

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Oct 26, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173

Recent Press Releases

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint

Oct 30, 2026 · GlobeNewsWire

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Oct 26, 2026 · GlobeNewsWire

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 22, 2026 · GlobeNewsWire

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Oct 19, 2026 · GlobeNewsWire

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

Sep 10, 2026 · GlobeNewsWire

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 2, 2026 · GlobeNewsWire

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 12, 2026 · GlobeNewsWire

SEC Filings (46)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	8-K	Material event	Document Index
Oct 30, 2026	8-K	Material event	Document Index
Oct 28, 2026	EFFECT		Document Index
Oct 26, 2026	S-3	Shelf registration	Document Index
Oct 26, 2026	10-Q	Quarterly report	Document Index
Oct 26, 2026	8-K	Material event	Document Index
Sep 16, 2026	8-K	Material event	Document Index
Aug 12, 2026	S-8	Employee stock plan	Document Index
Aug 12, 2026	10-Q	Quarterly report	Document Index
Aug 12, 2026	8-K	Material event	Document Index
Jun 16, 2026	8-K	Material event	Document Index
May 12, 2026	10-Q	Quarterly report	Document Index
May 12, 2026	8-K	Material event	Document Index
Apr 23, 2026	ARS	Annual report to holders	Document Index
Apr 23, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Apr 23, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Apr 7, 2026	SC 13G	Passive 5%+ stake	Document Index
Apr 1, 2026	EFFECT		Document Index
Apr 1, 2026	424B3	Offering prospectus	Document Index
Mar 26, 2026	S-3	Shelf registration	Document Index
Mar 26, 2026	S-8	Employee stock plan	Document Index
Mar 26, 2026	10-K	Annual report	Document Index
Mar 26, 2026	8-K	Material event	Document Index
Mar 17, 2026	SC 13D/A	Activist / 5%+ stake	Document Index
Mar 16, 2026	8-K	Material event	Document Index
Jan 12, 2026	8-K	Material event	Document Index
Nov 13, 2025	424B5	Offering prospectus	Document Index
Nov 12, 2025	10-Q	Quarterly report	Document Index
Nov 12, 2025	8-K	Material event	Document Index
Nov 10, 2025	8-K	Material event	Document Index
Nov 4, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Aug 13, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Aug 12, 2025	10-Q	Quarterly report	Document Index
Aug 12, 2025	8-K	Material event	Document Index
Jul 15, 2025	8-K	Material event	Document Index
Jun 5, 2025	8-K	Material event	Document Index
May 13, 2025	10-Q	Quarterly report	Document Index
May 13, 2025	8-K	Material event	Document Index
Apr 23, 2025	ARS	Annual report to holders	Document Index
Apr 23, 2025	DEFA14A	Proxy / shareholder vote	Document Index